Scientists discovered that anti-CTLA-4 immunotherapy extended the lives of mice with glioblastoma by causing specialized CD4+ T immune cells to 1) infiltrate the brain and 2) tell brain-resident immune cells called microglia to destroy tumor cells. Their findings show the benefit of harnessing the body’s own immune cells to fight brain cancer and could lead to more effective immunotherapies.
